(Q45747079)

15 December 2017

title

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group (English)

1 reference

15 December 2017

0 references

1 reference

1 reference

1 reference

11

1 reference

15 December 2017

Christine Katlama

10

object named as

Katlama C

1 reference

15 December 2017

Benhamou Y

1

1 reference

15 December 2017

Bochet M

2

1 reference

15 December 2017

Di Martino V

3

1 reference

15 December 2017

Charlotte F

4

1 reference

15 December 2017

Azria F

5

1 reference

15 December 2017

Coutellier A

6

1 reference

15 December 2017

Vidaud M

7

1 reference

15 December 2017

Bricaire F

8

1 reference

15 December 2017

Opolon P

9

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

15 December 2017

published in

Hepatology

1 reference

15 December 2017

volume

30

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

1054-1058

1 reference

15 December 2017

Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency Virus

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Hepatitis C Virus Infection in Patients Infected with the Human Immunodeficiency Virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Quantitation of hepatitis C virus RNA in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

HCV genotypes in patients with liver disease of different stages and severity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Severe hepatitis in three AIDS patients treated with indinavir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300409

7 January 2021

Identifiers

DOI

10.1002/HEP.510300409

1 reference

15 December 2017

1 reference

15 December 2017